Home 
FOR AUTHORS General Physiology and Biophysics 2019 General Physiology and Biophysics Vol.38, No.1, p.1–13, 2019
FOR AUTHORS General Physiology and Biophysics 2019 General Physiology and Biophysics Vol.38, No.1, p.1–13, 2019
Journal info
Aims and Scope |
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 Neoplasma Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
General Physiology and Biophysics Vol.38, No.1, p.1–13, 2019 |
||
| Title: Integrative identification of unexpected kinase–inhibitor interactions in the MAPK-mediated proliferation and differentiation of Mc3T3-E1 osteoblasts | ||
| Author: Lei Zhao, Qun Huang, Shoujin Tian, Jianfei Ge, Hongyan Zhu, Qirong Dong | ||
| Abstract: Kinase-targeted therapy is a new and promising approach to disease treatment. However, some kinase inhibitors have been observed to cause an off-target adverse risk for skeletal system by influencing the growth of osteoblasts. It is known that the proliferation and differentiation of osteoblasts are essentially regulated by MAPK signaling pathway, and many off-target events are considered to influence this pathway. Here, the unexpected MAPK–inhibitor interactions in mouse MC3T3-E1 osteoblastic cells were investigated in detail using an integrative protocol. With bioinformatics analysis we successfully profiled a systematic noncognate interaction spectrum for off-target kinase inhibitors against mouse MAPK kinases, from which 13 potential MAPK–inhibitor interactions were identified. The inhibitors Nilotinib, Dasatinib and Bosutinib were suggested as promising candidates; their cytotoxicity on MC3T3-E1 and inhibitory activity against MAPK kinase were tested at cellular and molecular levels, respectively. We also tested two known MAPK inhibitors SP600125 and SB203580 as positive controls. Consequently, the Dasatinib was found to have high off-target risk for unexpectedly targeting osteoblast MAPK signaling pathway. |
||
| Keywords: Mitogen-activated protein kinase, Kinase inhibitor, Off-target, Unexpected interaction, Molecular modeling, Osteoblast, MC3T3-E1 | ||
| Published online: 03-Feb-2019 | ||
| Year: 2019, Volume: 38, Issue: 1 | Page From: 1, Page To: 13 | |
| doi:10.4149/gpb_2018030 |
||
|
|
 download file |
|